Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

NCT ID: NCT06008119

Last Updated: 2025-09-18

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 165 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-10-25
• Study Completion Date: 2026-12-24

Brief Summary

This is a multicenter, randomized, open-label, Phase 3 study

Detailed Description

This is a multicenter, randomized, open-label, Phase 3 study to evaluate Tunlamatinib plus Vemurafenib versus Investigator's choice of Chemotherapy based treatment as controls in patients with BRAFV600E mutant Metastatic Colorectal Cancer (CRC) whose disease has progressed after 1 or more prior regimens in the metastatic setting.

Conditions

Colorectal Cancer Metastatic

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental

Tunlamatinib plus Vemurafenib

Group Type: EXPERIMENTAL

Tunlametinib plus Vemurafenib

Intervention Type: DRUG

12mg BID Tunlametinib+720mg BID Vemurafenib

Control

Investigators' choice

Group Type: ACTIVE_COMPARATOR

Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab

Intervention Type: DRUG

According to investigators' suggestion

Interventions

Tunlametinib plus Vemurafenib

12mg BID Tunlametinib+720mg BID Vemurafenib

Intervention Type: DRUG

Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab

According to investigators' suggestion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Before study entry, written informed consent must be obtained from the patient prior to performing any study-related procedures.

2. Male or female patients with 18 to 70 years of age at time of informed consent;

3. Histological or cytologically confirmed metastatic CRC

4. Presence of BRAFV600E in tumor tissue as previously determined by a local assay at any time prior to Screening or by the central laboratory (BRAFV600 is permitted)

5. Able to provide a sufficient amount of representative tumor specimen (primary or metastatic, archival or newly obtained) for confirmatory central laboratory testing of BRAF mutation status.

6. Progression of disease after 1 or more prior regimens in the metastatic setting

7. At least 1 site of radiographically measurable disease by RECIST 1.1

8. Eastern Cooperative Oncology Group (ECOG) Performance Status(PS) of 0 to 1;

9. Life expectancy ≥ 3 months;

10. Can swallow the medicine,

11. Adequate hematologic, renal, cardiac and liver function as defined by laboratory values performed within 7 days prior to initiation of dosing:

12. Be willing and able to complete all the study procedures and follow-up examinations.

Exclusion Criteria

1. Prior treatment with any BRAF and MEK inhibitor;

2. Known contraindication to receive the treatment of control arm (according to latest PI).

3. Symptomatic brain metastasis or leptomeningeal disease

4. History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤12 months prior to randomization

5. Known history of acute or chronic pancreatitis

6. Uncontrolled GI bleeding, Dysphagia，refractory nausea, vomiting, small bowel resection or any other gastrointestinal ailment that would preclude study drug absorption.

7. Serious cardiovascular disease , including uncontrolled congestive heart failure, uncontrolled hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmia , deep vein thrombosis or pulmonary emboli or cerebrovascular events ≤ 6 months prior to starting study treatment;

8. History or current evidence of retinal vein occlusion or current risk factors for retinal vein occlusion (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes)

9. Concurrent neuromuscular disorder that is associated with the potential of elevated creatine (phosphor)kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy)

10. Uncontrolled blood pressure despite medical treatment

11. Concurrent or previous other malignancy within 5 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, or other noninvasive or indolent malignancy

12. Residual common terminology criteria for adverse events (CTCAE) ≥ Grade 2 toxicity from any prior anticancer therapy, with the exception of Grade 2 alopecia or Grade 2 neuropathy

13. Anti-HIV(+) , Anti-TP( +); Active hepatitis B or hepatitis C infection …….

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai Kechow Pharma, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Beijing Oncology Hospital

Beijing, Beijing Municipality, China

Site Status: RECRUITING

Countries

China

Facility Contacts

Lin Shen

Role: primary

doctorshenlin@sina.cn

86+10-88196561

Other Identifiers

HL-085-304

Identifier Type: -

Identifier Source: org_study_id